ATF936   Click here for help

GtoPdb Ligand ID: 9475

Synonyms: ATF-936 | compound 10a [PMID: 20158186]
Compound class: Synthetic organic
Comment: ATF936 is an orally bioavailable, negative allosteric modulator (NAM) of the calcium sensing receptor (CaSR) that was developed by Novartis [3]. It acts to promote a rapid and transient release of parathyroid hormone which stimulates a calcilytic effect in vivo [2]. CaSR antagonists/NAMs are being investigated as bone-forming osteoporosis therapeutics.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 44.12
Molecular weight 408.18
XLogP 7.46
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES C#CCOc1ccc2c(c1)c(nc(=O)n2Cc1ccccc1)c1ccc(cc1)C(C)C
Isomeric SMILES C#CCOc1ccc2c(c1)c(nc(=O)n2Cc1ccccc1)c1ccc(cc1)C(C)C
InChI InChI=1S/C27H24N2O2/c1-4-16-31-23-14-15-25-24(17-23)26(22-12-10-21(11-13-22)19(2)3)28-27(30)29(25)18-20-8-6-5-7-9-20/h1,5-15,17,19H,16,18H2,2-3H3
No information available.
Summary of Clinical Use Click here for help
ATF936 has completed Phase 1 evaluation in healthy subjects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00417261 Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects. Phase 1 Interventional Novartis This study has been completed, and results were published in 2011. The calcilytic effect of oral ATF936 was determined to be comparable to the PTH profile produced by s.c. injected teriparatide. 1-2